Current status of immunotherapy for allergies and anaphylactic reactions

Advances in Internal Medicine

Volumn 41, Issue , 1996, Pages 681-713

  Norman, Philip S ^a  

^a JOHNS HOPKINS ASTHMA AND ALLERGY CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPHYLAXIS; HUMAN; HYPERSENSITIVITY; IMMUNOTHERAPY; REVIEW;

ANAPHYLAXIS; HUMANS; HYPERSENSITIVITY; IMMUNOTHERAPY;

EID: 0030330829     PISSN: 00652822     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (129)

1. Noon L: Prophylactic inoculation against hay fever. Lancet 1:1572-1573, 1911.
2. Freeman J: Further observations on the treatment of hay fever by hypodermic inoculations of pollen vaccine. Lancet 2:814, 1911.
3. Cooke RA: Hay fever and asthma: The uses and limitations of desensitization. N Y Med J 107:577-583, 1918.
4. Cooke RA: Studies in specific hypersensitiveness: III. On constitutional reactions: The dangers of the diagnostic cutaneous test and therapeutic injection of allergens.J fmmunol 7:119-146, 1922.
5. Bradley BL, Azzawi M, Jacobson M, et al: Eosinophils, T-lymphocytes, mast cells, neutrophils, and macrophages in bronchial biopsy specimens from atopic subjects with asthma: Comparison with biopsy specimens from atopic subjects without asthma and normal control subjects and relationship to bronchial hyperresponsiveness.J Allergy Clin ImmunoJ 88:661-674, 1991.
6. Arock M, Merle-Béral H, Dugas B, et al: IL-4 release by human leukemia and activated normal basophils.J Immunol 151:1441-1447,1993.
7. Flaut M, Pierce JH, Watson CJ, et al: Mast cell lines produce lymphokines in response to cross-linkage of FCeRI or to calcium ionophores. Nature 339:64-67, 1989.
8. Naclerio RM, Proud D, Togias AG, et al: Inflammatory mediators in late antigen-induced rhinitis. N Engl J Med 313:65-70, 1985.
9. Pipkorn U, Proud D, Lichtenstein LM, et al: Inhibition of mediator release in allergic rhinitis by pretreatment with topical glucocorticosteroids. N EngJ J Med 316:1506-1510, 1987.
10. Norman PS, Winkenwerder WL, Lichtenstein LM: Immunotherapy of hay fever with ragweed antigen E: Comparisons with whole pollen extract and placebos.J Allergy 42:93-108, 1968.
11. Lichtenstein LM, Norman PS, Winkenwerder WL: A single year of immunotherapy for ragweed hay fever. Immunologie and clinical studies. Ann Intern Med 75:663-671, 1971.
12. Norman PS: Specific therapy in allergy. Pro (with reservations). Med Clin North Am 58:111-125, 1974.
13. Lowell FC, Franklin W: A double-blind study of the effectiveness and specificity of injection therapy in ragweed hay fever. N Engl J Med 273:675-679, 1965.
14. Norman PS, Lichtenstein LM: The clinical and immunologie specificity of immunotherapy.J Allergy Clin Immunol 61:370-377, 1978.
15. Naclerio RM, Meier HL, Kagey-Sobotka A, et al: Mediator release after nasal airway challenge with allergen. Am Rev Respir Dis 128:597-602, 1983.
16. Creticos PS, Adkinson NF Jr, Kagey-Sobotka A, et al: Nasal challenge with ragweed pollen in hay fever patients. Effect of immunotherapy.J Clin Invest 76:2247-2253, 1985.
17. Creticos PS, Marsh DG, Proud D, et al: Responses to ragweed-pollen nasal challenge before and after immunotherapy.J Allergy Clin Immunol 84:197-205, 1989.
18. Aas K: Hyposensitization in house dust allergy asthma: A double blind controlled study with evaluation of the effect on bronchial sensitivity to house dust. Acta Paediatr Scand 60:264-268, 1971.
19. Taylor WW, Ohman JL, Lowell FC: immunotherapy in cat-induced asthma. Double-blind trial with evaluation of bronchial responses to cat allergen and histamine.J Allergy Clin Immunol 61:283-287,1978.
20. Creticos PS, Reed CE, Norman PS: The MAID cooperative study of the role of immunotherapy in seasonal ragweed-induced adult asthma.J Allergy Clin Immunol 91:226, 1993.
21. Metzger WJ, Donnelly BA, Richerson HB: Modification of late asthmatic responses (LAR) during immunotherapy for Alternaria-induced asthma.J Allergy Clin Immunol 71:119,1983.
22. Warner JD, Price JF, Soothill JF, et al: Controlled trial of hyposensiti-zation to Dermatophagoides pteronyssinus in children with asthma. Lancet 2:912, 1978.
23. Pienkowski MM, Norman PS, Lichtenstein LM: Suppression of latephase skin reactions by immunotherapy with ragweed extract.J Allergy Clin Immunol 76:729-734, 1985.
24. Iliopoulos O, Proud D, Adkinson NF Jr, et al: Effects of immunotherapy on the early, late and rechallenge nasal reaction to provocation with allergen: Changes in inflammatory mediators and cells.J Allergy Clin Immunol 87:855-866, 1991.
25. Parker WAJ, Whisman BA, Apaliski SJ, et al: The relationships between late cutaneous responses and specific antibody responses with outcome of immunotherapy for seasonal allergic rhinitis.J Allergy Clin Immunol 84:667-677, 1989.
26. Furin MJ, Norman PS, Creticos PS, et al: Immunotherapy decreases antigen-induced eosinophil cell migration into the nasal cavity.J Allergy Clin Immunol 88:27-32, 1991.
27. Connell JT: Quantitative intranasal pollen challenge: II. Effect of daily pollen challenge, environmental pollen exposure, and placebo challenge on the nasal membrane.J Allergy 41:123, 1968.
28. Connell JT: Quantitative intranasal challenges: III. The priming effect in allergic rhinitis.J Allergy 43:33, 1969.
29. Cartier A, Bandouvakis J, Ryan G, et al: Asthma and increased nonallergic bronchial responsiveness to methacholine during natural exposure to ragweed pollen. Am flev Respir Dis 121(suppl):61, 1980.
30. Platts-Mills TE, Tovey ER, Mitchell EB, et al: Reduction of bronchial hyperreactivity during prolonged allergen avoidance. Lancet 2:675678, 1982.
31. Hedlin G, Graft-Lonnevig V, Heilborn H, et al: Immunotherapy with cat- and dog-dander extracts.J Allergy Clin Immunol 87:955-964, 1991.
32. Majchel AM, Proud D, Friedhoff L, et al: The nasal response to histamine challenge-effect of the pollen season and immunotherapy.JAllergy Clin Immunol 90:85-91, 1992.
33. Cooke RA, Barnard JH, Hebald S, et al: Serological evidence of immunity with coexisting sensitization in a type of human allergy (hay fever).J Exp Med 62:733-751, 1935.
34. Loveless MH: Immunological studies of pollinosis: IV. The relationship between thermostable antibody in the circulation and clinical immunity. J Immunol 47:165-180, 1943.
35. Lichtenstein LM, Norman PS, Winkenwerder WL, et al: In vitro studies of human ragweed allergy: Changes in cellular and humoral activity associated with specific desensitization.J Clin Invest 45:1126-1136, 1966.
36. Lichtenstein LM, Ishizaka K, Norman PS, et al: IgE antibody measurements in ragweed hay fever. Relationship to clinical severity and the results of immunotherapy.J Clin Invest 52:472-482, 1973.
37. Gleich GJ, Jacob GL, Yunginger JW, et al: Measurement of the absolute levels of IgE antibodies in patients with ragweed hay fever: Effect of immunotherapy on seasonal changes and relationship to IgG antibodies.J Allergy Clin Immunol 60:188-198, 1977.
38. Platts-Mills TA, von Maur RK, Ishizaka K, et al: IgA and IgG antiragweed antibodies in nasal secretions. Quantitative measurements of antibodies and correlation with inhibition of histamine release.J Clin Invest 57:1041-1050, 1976.
39. Platts-Mills TAE: Local production of IgG, IgA, and IgE antibodies in grass pollen hay fever.J Immunol 122:2218-2225, 1979.
40. Sadan N, Rhyne MB, Mellits ED, et al: Immunotherapy of pollinosis in children. Investigation of the immunologie basis of clinical improvement. N Engl J Med 280:623-627, 1969.
41. Lichtenstein LM, Norman PS, Winkenwerder WL: Clinical and in vitro studies on the role of immunotherapy in ragweed hay fever. Am J Med 44:514-524, 1968.
42. Devey ME, Wilson DV, Wheeler AW: The IgG subclass of antibodies to grass pollen allergens produced in hay fever patients during hyposensitization. Clin Allergy 6:227-236, 1976.
43. Aalberse RC, van der Gaag R, van Leeuwen J: Serologie aspects of IgG4 antibodies. I. Prolonged immunization results in an IgG4-restricted response.J Immunol 130:722-726, 1983.
44. van der Zee JS, van Swieten P, Aalberse RC: Serologie aspects of IgG4 antibodies. II. IgG4 antibodies form small, nonprecipitating immune complexes due to functional monovalency.J Immunol 137:3566-3571, 1986.
45. Creticos PS, Van Metre TE Jr, Mardiney MR, et al: Dose response of IgE and IgG antibodies during ragweed immunotherapy.J Allergy Clin Immunol 73:94-104, 1984.
46. Gleich GJ, Zimmerman BS, Henderson LL, et al: Effects of immunotherapy on immunoglobulin E and immunglobulin G antibodies to ragweed antigens: A six year prospective study.J Allergy Clin Immunol 70:261-271, 1982.
47. Rocklin RE, Pence H, Kaplan H, et al: Cell-mediated immune response of ragweed-sensitive patients to ragweed antigen E: In vitro lymphocyte transformation and elaboration of lymphocyte mediators.J Clin Invest 53:735-744, 1974.
48. Rocklin RE, Sheffer AL, Greineder DK, et al: Generation of antigenspecific suppressor cells during allergy desensitization. N Engl J Med 302:1213-1219, 1980.
49. Greenstein JL, Morgenstern JP, LaRaia J, et al: Ragweed immunotherapy decreases T cell reactivity to recombinant Amb a I.J Allergy Clin Immunol 89:322, 1992.
50. + T cells from allergic individuals.J Exp Med 178:2123-2130, 1993.
51. Varney VA, Hamid QA, Gaga M, et al: Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses.J Clin Invest 92:644-651, 1993.
52. Durham SR, Varney VA, Sun Y, et al: Effect of grass pollen immunotherapy on cell infiltration and cytokine mRna expression during allergen-induced late nasal response.J Allergy Clin Immunol 93:230, 1994.
53. Charlesworth EN, Nish WA, Charlesworth MG, et al: Standard high dose immunotherapy decreases the production of IL-3, IL-5, and GMCSF during the cutaneous late-phase response (LPR) to antigen.J AlJergy Clin Immunol 91:252, 1993.
54. Frankland AW, Augustin R: Prophylaxis of summer hay-fever and asthma: A controlled trial comparing crude grass-pollen extracts with the isolated main protein component. Lancet 1:1055-1057, 1954.
55. Johnstone DE: Study of the role of antigen dosage in the treatment of pollenosis and pollen asthma.J Dis Child 94:1-5, 1957.
56. Lowell FC, Franklin W: A double blind study of treatment with aqueous allergenic extracts in cases of allergic rhintis.J Allergy 34: 165-182, 1963.
57. Dieges PH: A prospective study on some immunological changes occurring in the first year of grass pollen desensitization. Acta Allergol 31:130-140, 1976.
58. Van Der Giesen M, Homan WL, Van Kernebeck G, et al: Subclass typing of IgG antibodies formed by grass pollen-allergic patients during immunotherapy. Int Arch Allergy 50:625-640.
59. Pence HL, Mitchell DQ, Greely RL, et al: Immunotherapy for mountain cedar pollinosis: A double-blind controlled study.J Allergy Clin Immunol 58:39-50, 1976.
60. Ahlstedt S, Eriksson NE: Immunotherapy in atopic allergy-antibody titres and avidities during hyposensitization with birch and timothy pollen allergens. Int Arch Allergy 55:400-411, 1977.
61. Forgacs P, Swan AV: Treatment of house dust allergy. BMJ 3:774- 777, 1968.
62. May CD, Lyman M, Alberto R, et al: Immunochemical evaluation of antigenicity of house dust extract: Specificity of dermal wheal reactions and responses to injections for immunotherapy.J Allergy 46:7389, 1970.
63. Chapman MD, Platts-Mills TAB, Gabriel M, et al: Antibody response following prolonged hyposensitization with Dermatophagoides pteronyssinus extract. Int Arch Allergy 61:431-440, 1980.
64. D'Souza MF, Pepys J, Wells ID, et al: Hyposensitization with Dermatophagoides pteronyssinus in house dust allergy: A controlled study of clinical and immunological effects. Clin Allergy 3:177-193, 1973.
65. Smith AP: Hyposensitization with Dermatophagoides pteronyssinus antigen: Trial in asthma induced by house dust. BMJ 4:204-206,1971.
66. Ohman JL Jr, Marsh DG, Goldman M: Antibody responses following immunotherapy with cat pelt extract.J Allergy Clin Immunol 69:319-326, 1982.
67. Ohman JL, Findlay SR, Leitermann KM: Immunotherapy in cat induced asthma. Double-blind trial with evaluation of in vivo and invitro responses.J Allergy Clin Immunol 74:230-239, 1984.
68. Sundin B, Lilja G, Graff-Lonnevig V, et al: Immunotherapy with partially purified and standardized animal dander extracts. I. Clinical results from a double-blind study on patients with animal dander asthma.J Allergy Clin Immunol 77:478-487, 1986.
69. Valovirta E, Viander M, Koivikko A, et al: Immunotherapy in allergy to dog. Immunologie and clinical findings of a double-blind study. Ann Allergy 57:173-179,1986.
70. Koivikko A, Agrell B, Dreborg S, et al: A double-blind multicenter immunotherapy trial in children with purified and standardized Cladosporium herbarum (Hormodendrum) preparation. I. Clinical results.J Allergy Clin Immunol 73:142, 1984.
71. Mailing H-J: Diagnosis and immunotherapy of mold allergy. V. Clinical efficacy and side effects of immunotherapy with Cladosporium herbarum. Allergy 41:505-519, 1986.
72. Aukrust L, Borch SM: Partial purification and characterization of two Cladosporium herbarum allergens. Int Arch Allergy Appl Immunol 60:68, 1979.
73. Yunginger JW, Jones RT, Gleich GJ: Studies on Alternaria allergens. II. Measurement of the realative potency of commercial Alternaria extracts by the direct RAST and by RAST inhibition.J Allergy Clin Immunol 58:405-413, 1976.
74. Yunginger JW, Jones RT, Nesheim ME, et al: Studies on Alternaria allergens. III. Isolation of a major allergenic fraction (Alt-1).J Allergy Clin Immunol 66:136-147, 1980.
75. Hunt KJ, Valentine MD, Sobotka AK, et al: A controlled trial of immunotherapy in insect hypersensitivity. N Eng] J Med 299:157-161, 1978.
76. Norman PS, Lichtenstein LM, Ishizaka K: Diagnostic tests in ragweed hay fever. A comparison of direct skin tests, IgE antibody measurements, and basophil histamine release.J Allergy Clin Immunol 52:210-224, 1973.
77. Marsh DG, Belin L, Bruce ÇA, et al: Rapidly released allergens from short ragweed pollen: I. Kinetics of release of known allergen in relation to biological activity.J Allergy Clin Immunol 67:206-216,1981.
78. Connell JT, Sherman WB, Myers PA: Antibody studies in constitutional reactions resulting from injections of ragweed pollen extract.J Allergy 33:365-377, 1962.
79. Lockey RF Benedict LM, Turkeltaub PC, et al: Fatalities from immunotherapy (IT) and skin testing (ST).J Allergy Clin Immunol 79:660-677, 1987.
80. Tinkelman DG, Cole WQ III, Tunno J: Immunotherapy: A one-year prospective study to evaluate risk factors of systemic reactions.J Allergy Clin Immunol 95:8-14, 1995.
81. Van Metre TE Jr, Adkinson NF Jr, Amodio FJ, et al: A comparison of immunotherapy schedules for injection treatment of ragweed pollen hay fever.J Allergy Clin Immunol 69:181-193, 1982.
82. Executive Committee of the American Academy of Allergy and Immunology: Guidelines to minimize the risk from systemic reactions caused by immunotherapy with allergenic extracts.J Allergy Clin Immunol 93:811-812, 1994.
83. Stein MR, Brown GL, Lima JE, et al: A laboratory evaluation of immune complexes in patients on inhalant immunotherapy.J Allergy Clin Immunol 62:211-216, 1978.
84. Yang WH, Dorval G, Osterland CK, et al: Circulating immune complexes during immunotherapy.J Allergy Clin Immunol 63:300-307, 1979.
85. Norman PS, Winkenwerder WL, Lichtenstein LM: Trials of alumprecipitated pollen extracts in the treatment of hay fever.J Allergy Clin Immunol 50:31-44, 1972.
86. Marsh DG, Lichtenstein LM, Campbell DH: Studies on 'allergoids' prepared from naturally occurring allergens: I. Assay of allergenicity and antigenicity of formalinized rye group I component. Immunology 18:705-722, 1970.
87. Marsh DG, Lichtenstein LM, Norman PS: Induction of IgE-mediated immediate hypersensitivity to group I rye grass pollen allergen and allergoids in non-allergic man. Immunology 22:1013-1028, 1972.
88. Norman PS, Marsh DG, Lichtenstein LM, et al: Controlled evaluation of allergoid in the immunotherapy of ragweed hay fever.J Allergy Clin Immunol 70:248-260, 1982.
89. Metzger WJ, Patterson R, Zeiss CR, et al: Comparison of polymerized and unpolymerized antigen E for immunotherapy of ragweed allergy. NEnglJMed 295:1160-1164, 1976.
90. Bacal E, Zeiss CR, Suszko I, et al: Polymerized whole ragweed: An improved method of immunotherapy.J Allergy Clin Immunol 62:289-294, 1978.
91. Miller ACML, Tees EC: A metabolizable adjuvant: Clinical trial of grass pollen-tyrosine adsorbate. Clin Allergy 4:49-55, 1974.
92. Cockroft DW, Cuff MT, Tarlo SM, et al: Allergen injection therapy with glutaraldehyde-modified-ragweed pollen-tyrosine adsorbate. A double-blind trial.J Allergy Clin ImmunoJ 60:56-62, 1977.
93. Golden DBK, Johnson K, Addison BI, et al: Clinical and immunologie observations in patents who stop venom immunotherapy.J Allergy Clin Immunol 77:435-442, 1986.
94. Golden DBK, Kwiterovich KA, Kagey-Sobotka A, et al: Immunologie response to sequential stings after stopping venom immunotherapy (VIT) in adults.J Allergy Clin Immunol 81:201, 1988.
95. Cooke RA, Stull A: Preparation and standardization of pollen extracts for the treatment of hay fever.J Allergy 4:87-91, 1933.
96. Baer H, Godfrey H, Maloney CJ, et al: The potency and antigen E content of commercially prepared ragweed extracts.J Allergy 45:347-354, 1970.
97. Baer H, Maloney CJ, Norman PS, et al: The potency and group I antigen content of six commercially prepared grass pollen extracts.J Allergy Clin Immunol 54:157-164, 1974.
98. Platts-Mills TAE: Allergens, in Frank MM, Austen KF, Claman HN, et al (eds): Samter's Immunologie Diseases, ed 5. Boston, Little, Brown, 1994, pp 1231-1256.
99. King TP, Norman PS, Connell JT: Isolation and characterization of allergens from ragweed pollen. II. Biochemistry 3:458-468, 1964.
100. Ltfwenstein H, Marsh DG: Antigens of Ambrosia elatior (short ragweed) pollen. III. Crossed radioimmunoelectrophoresis of ragweedallergic patient's sera with special attention to quantification of IgE responses.J Immunol 130:727-731, 1983.
101. Helm RM, Gauerke MB, Baer H, et al: Production and testing of an international reference standard of short ragweed pollen extract.J Allergy Clin Immunol 73:790-800, 1984.
102. Gjesing B, Jäger L, Marsh DG, et al: The international collaborative study establishing the first international standard for timothy (Phleum pratense) grass pollen allergenic extract.J Allergy Clin Immunol 75:258-267, 1985.
103. Ford A, Seagroatt V, Platts-Mills TAE, et al: A collaborative study on the first international standard of Dermatophagoides pteronyssinus (house dust mite) extract.J Allergy Clin Immunol 75:676-686, 1985.
104. Larsen JN, Ford A, Gjesing B, et al: The collaborative study of the international standard of dog, Canis domesticus, hairJdander extract.J Allergy Clin Immunol 82:318-330, 1988.
105. Arntzen FC, Wilhelmsen TW, Löwenstein H, et al: The international collaborative study on the first international standard of birch (Betula verrucosa) pollen extract.JAllergy Clin Immunol 83:66-82, 1989.
106. Foucard T, Johansson SCO, Bennich H, et al: In vitro estimation of allergens by a radioimmune antiglobulin technique using human IgE antibodies. Int Arch Allergy Appl Immunol 43:360-370, 1972.
107. Gleich GJ, Larson JB, Jones RT, et al: Measurement of the potency of allergy extracts by their inhibitory capacities in the radioallergosorbent test.J Allergy Clin Immunol 53:158-169, 1974.
108. Aas K, Belin L: Suggestion for biologic qualitative testing and standardization of allergen extracts. Acta Allergol 29:238, 1974.
109. Turkeltaub PC: The allergy unit-clinical relevance: Issues in allergen standardization, in Lockey RF, Bukantz SC (eds): Allergen Immunotherapy. New York, Marcel Dekker, 1991, pp 171-190.
110. Liu DT: Regulation of allergenic products in the USA: CBER initiatives, in Kurth R, Haustein D (eds): Regulatory Control and Standard-ization of Allergenic Extracts. New York, Gustave Fischer Verlag, 1994, pp 7-12.
111. Van Metre TE Jr, Adkinson NF Jr, Amodio FJ, et al: A comparative study of the effectiveness of the Kinkel method and the current standard method of immunotherapy for ragweed pollen hay fever.J Allergy Clin ImmunoJ 66:500-513, 1980.
112. Moss RB, Hsu Y-P, Kwasnicki JM, et al: Isotypic and antigenic restriction of the blocking antibody response to ryegrass pollen: Correlation of rye group I antigen-specific IgGl with clinical response.J Allergy Clin Immunol 79:387-398, 1987.
113. Osterballe O: Immunotherapy with grass pollen allergens. Clinical results from a prospective 3 year double blind study. Allergy 37:379-388, 1982.
114. Van Metre TE Jr, Marsh DG, Adkinson NF Jr, et al: Immunotherapy for cat asthma.J Allergy Clin Immunol 82:1055-1068, 1988.
115. Mosbech H, Dreborg S, Frtflund L, et al: Hyposensitization in asthmatics with mPEG modified and unmodified house dust mite extract. I. Clinical effect evaluated by diary cards and a retrospective assessment. Allergy 44:487-498, 1989.
116. Wahn U, Schweter C, Lind P, et al: Prospective study on immunologie changes induced by two different Dermatophagoides pteronyssinus extracts prepared from whole mite culture and mite bodies.J Allergy Clin Immunol 82:360-370, 1988.
117. Haugaard L, Dahl R, Jacobsen L: A controlled dose-response study of immunotherapy with standardized, partially purified extract of house dust mite: Clinical efficacy and side effects.J Allergy Clin Immunol 91:709-722, 1993.
118. King TP, Sobotka AK, Alagon A, et al: Protein allergens of white-face hornet, yellow hornet, and yellow jacket venoms. Biochemistry 17: 5165-5174, 1978.
119. Huang S-K, Marsh DG: Genetics of allergy. Ann Allergy 70:347-358, 1993.
120. Yssel H, Johnson KE, Schneider PV, et al: T cell activation-inducing epitopes of the house dust mite allergen Der p I.J Immunol 148:738745, 1992.
121. Higgins JA, Lamb JR, Marsh SGE, et al: Peptide-induced nonresponsiveness of HLA-DP restricted human T cells reactive with Dermatophagoides spp. (house dust mite).J Allergy Clin Immunol 90:749-756, 1992.
122. Dhillon M, Roberts C, Nunn T, et al: Mapping human T cell epitopes on phospholipase A2: The major bee-venom allergen.J Allergy Clin Immunol 90:42-51, 1992.
123. O'Hehir RE, Carman RD, Greenstein JL, et al: The specificity and regulation of T-cell responsiveness to allergens. Annu Rev Immunol 9:6795, 1991.
124. O'Hehir RE, Yssel H, Verma S, et al: Clonal analysis of differential lymphokine production in peptide and superantigen induced T cell anergy. Int Immuno J 3:819-826, 1991.
125. Gaur A, Wiers B, Liu A, et al: Amelioration of autoimmune encephalomyelitis by myelin basic protein synthetic peptide-induced anergy. Science 258:1491-1494, 1992.
126. Morgenstern JP, Griggith IJ, Brauer AW, et al: Determination of the amino acid sequence of Pel d I, the major allergen of the domestic cat: Protein sequence analysis and cDNA cloning. Proc NatI Acad Sei USA 88:9690-9696, 1991.
127. Briner TJ, Kuo M-C, Keating KM, et al: Peripheral T-cell tolerance induced in naive and primed mice by subcutaneous injection of peptides from the major cat allergen Pel d I. Proc Natl Acad Sei USA 90:7608-7612, 1993.
128. Norman PS, Ohman JL, Long AA, et al: Early clinical experience with T cell reactive peptides from cat allergen Pel d 1.J Allergy Clin Immunol 93:231, 1994.
129. Norman PS, Ohman JL, Long AA, et al: Follow on study of the first clinical trial with T cell denned peptides from cat allergen Pel d 1.J Allergy Clin Immunol 95:259, 1995.